1. Quill T, Abernethy A. Generalist plus specialist palliative care – creating a more sustainable model. N Engl J Med 2013; 368(13): 1173–1175.
2.
Ciałkowska-Rysz A. An appraisal of the situation of palliative care in Poland in 2018. Med Paliat 2019; 11(4): 163–169.
3.
Dzierżanowski T. Dostępność opieki paliatywnej dla dorosłych w Polsce. Palliat Med 2020; 12(2): 75–83 (in Polish).
4.
Rochan PA, Gill SS, Litner J, et al. A systematic revive of the evidence for hypodermoclisis to treat dehydratation in older people. J Gerontol A Biol Sci Med Sci 1997; 52(3): M169–M176.
5.
Remington R, Hultman T. Hypodermoclysis to treat dehydration: a review of the evidence. J Am Geriatr Soc 2007; 55(12): 2051–2055.
6.
Wells C, MacDougall D. Hypodermoclysis for Frail Patients and Patients in Long Term Care: A Review of Clinical Effectiveness, Cost Effectiveness, and Guidelines. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020.
7.
Esmeray G, Senturan L, Doventas A. A study on efficacy of hydration administered by subcutaneous infusion in geriatric patients. Turk Geriatri Dergisi 2018; 21(3): 438–445.
8.
Bruno V. Hypodermoclysis: a literature review to assist in clinical practice. Einstein 2015; 13(1): 122–128.
9.
Sasson M, Shvartzman P. Hypodermoclysis: an alternative infusion technique. Am Fam Physician 2001; 64(9): 1575–1578.
10.
Caccialanza R, Constans T, Cotogni P, et al. Subcutaneous infusion of fluids for hydration or nutrition: a review. J Parenter Enter Nutr 2018; 42: 296–307.
11.
Instituto Nacional de Câncer (INCA). Terapia Subcutânea no Câncer Avançado. Rio de Janeiro: INCA; 2009. Serie Cuidados Paliativos; 9–27.
12.
Życzkowska J, Wordliczek J. Podskórne i dożylne stosowanie leków przeciwbólowych w medycynie paliatywnej. Adv Palliat Med 2009; 8, 4: 153–160 (in Polish).
13.
Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84(5): 587–593.
14.
Grądalski T, Szostakiewicz M. Off-label drug use in palliative care – a narrative review. Med Paliat 2020; 12(4): 155–166.
15.
Leheup BF, Ducousso S, Picard S, et al. Subcutaneous administration of paracetamol-Good local tolerability in palliative care patients: An observational study. Palliat Med 2018; 32(7): 1216–1221.
16.
El Khoury J, Hlais S, Helou M, et al. Evaluation of efficacy and safety of subcutaneous acetaminophen in geriatrics and palliative care (APAPSUBQ). BMC Palliat Care 2022; 21(1): 42.
17.
Moselli NM, Cruto M, Massucco P, et al. Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain. Clin J Pain 2010; 26(4): 267–274.
18.
Chiarello E, Bernasconi S, Gugliotta B, et al. Subcutaneous injection of diclofenac for the treatment of pain following minor orthopedic surgery (DIRECT study): a randomized trial. Pain Pract 2015; 15(1): 31–39.
19.
Negro S, Martín A, Azuara ML, et al. Stability of tramadol and haloperidol for continuous subcutaneous infusion at home. J Pain Symptom Manage 2005; 30(2): 192–199.
20.
Woroń J, Dobrogowski J, Wordliczek J. Wybór opioidów i ich dawkowanie w leczeniu bólu. Med Dypl 2011; 4(181): 77–82 (in Polish).
21.
Dobrogowski J, Krajnik M, Jassem J, et al. Stanowisko dotyczące postpowania przeciwbólowego u chorych na nowotwory. Onkol Prakt Klin 2009; 5: 55–68 (in Polish).
22.
Bruera E, MacEachern T, Ripamonti C, et al. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993; 119(9): 906–907.
23.
Prommer E. Midazolam: an essential palliative care drug. Palliat Care Soc Pract 2020; 14: 2632352419895527.
24.
Klauser CK, Fox NS, Istwan N, et al. Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. Am J Perinatol 2011; 28(9): 715–721.
25.
McCallum RW, Valenzuela G, Polepalle S, et al. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther 1991; 258(1): 136–142.
26.
Zaporowska-Stachowiak I, Stachowiak-Szymczak K, Oduah MT, et al. Haloperidol in palliative care: Indications and risks. Biomed Pharmacother 2020; 132: 110772.
27.
Murray-Brown F, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev 2015; 2015(11): CD006271.
28.
Hardy JR, O’Shea A, White C, et al. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage 2010; 40(1): 111–116.
29.
Garcia C, Lynn R, Breitbart W. Psychotropic Medications in Palliative Care. Prim Psychiatr 2009; 16(5): 25–32.
30.
Eisenchlas JH, Garrigue N, Junin M, et al. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med 2005; 19(1): 71–75.
31.
EMC. SPC Levomepromazine Hydrochloride 25 mg/ml Solution for Injection. 2017. Available from: https://www.medicines.org.uk/emc/medicine/27512/SPC/Levomepromazine+Hydrochloride+25mg+ml+Solution+for+Injection/
32.
Badian M, Dzierżanowski T. Hiccup in palliative care patients. Med Paliat 2018; 10(2): 43–48.
33.
Veevers AE, Oxberry SG. Ranitidine: forgotten drug of delayed gastric emptying. BMJ Support Palliat Care 2017; 7(3): 255–257.
34.
Wildiers H, Dhaenekint C, Demeulenaere P, et al. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage 2009; 38(1): 124–133.
35.
De Conno F, Caraceni A, Zecca E, et al. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991; 6(8): 484–486.
36.
Howard P, Curtin J. Bleeding management in palliative medicine: subcutaneous tranexamic acid – retrospective chart review. BMJ Support Palliat Care 2022; doi: 10.1136/bmjspcare-2021-003427.
37.
Dietz I, Schmitz A, Lampey I, et al. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care 2013; 12: 2.
38.
Afari ME, Aoun J, Khare S, et al. Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review. Heart Fail Rev 2019; 24(3): 309–313.
39.
Walker J, Lane P, McKenzie C. Evidence-based practice guidelines: a survey of subcutaneous dexamethasone administration. Int J Palliat Nurs 2010; 16(10): 494–498.
40.
Leppert W, Swoboda D. Management of cancer patients with symptoms of bowel obstruction. Med Paliat 2010; 2(4): 177–189.
41.
Azevedo EF, Barbosa LA, Cassiani SH. Administration of antibiotics subcutaneously: an integrative literature review. Acta Paul Enferm 2012; 25(5): 817–822.
42.
Harb G, Lebel F, Battikha J, et al. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 2010; 26(2): 279–288.
43.
Borner K, Lode H, Hampel B, et al. Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. Chemotherapy 1985; 31(4): 237–245.
44.
Woroń J, Dobrogowski J, Wordliczek J. Wybór opioidów i ich dawkowanie w leczeniu bólu. Med Dypl 2011; 20(4): 77–82 (in Polish).
45.
Moduł Leki. eMPendium Medycyna Praktyczna, refundacja na dzień 01.01.2022 (ostatnia aktualizacja 09.01.2022), za: Obwieszczenie Ministra Zdrowia z dnia 20 grudnia 2021 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 stycznia 2022 r. (in Polish).
